Monitor Jideytro launch trajectory and prescription data over next 2-3 quarters to gauge market penetration. The next major pipeline catalyst is the neladalkib PDUFA on November 27, 2026, which could further derisk the Nuvalent acquisition thesis. Ris-Rez phase III data in small-cell lung cancer from Hansoh Pharma also warrants attention.
Drugs in focus
GSK drug pipeline →Neladalkib
▲ Bullish Named in this 6-K- Impact
- Phase
- Filed/PDUFA (NDA under FDA Priority Review)
- Time to market
- If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
- Next catalyst
- None dated
What to watchFor GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.
- ● Jideytro 3/10 Approved (FDA); supported by the ARROS-1 phase I/II pivotal trial Named in filing
- ▲ risvutatug rezetecan 3/10 Phase 3 Named in filing
- ● Jemperli 5/10 Approved (Phase 3 / registrational Phase 2 for additional indications)
- ● Bexsero 4/10 Approved
- ● Cabenuva 4/10 Approved
- 11 more · All GSK drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 22 $50.76entry
- T+1 · 4mo ago −0.04%α +1.20% · $50.74
- T+5 · 4mo ago +4.85%α +7.25% · $53.22
- T+20 · 3mo ago +4.18%α +1.28% · $52.88
- T+60 · 5w ago −3.43%α −6.69% · $49.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, ahead of the original PDUFA date of September 18, 2026. This is GSK's first approved lung cancer therapy and the first product from the recently completed Nuvalent acquisition, validating the deal's strategic rationale. The approval is based on the ARROS-1 phase I/II trial (ORR 44%, 12-month DOR rate 69%) and adds a targeted option for an oncogenic driver with ~50,000 annual diagnoses worldwide.
Key Facts
- FDA approved Jideytro (zidesamtinib) for ROS1-positive locally advanced or metastatic NSCLC after prior ROS1 TKI
- Approval granted ahead of original target action date (Sept 18, 2026) under Breakthrough Therapy and Orphan Drug designations
- ARROS-1 trial showed ORR 44% (95% CI 34-53%) in pre-treated population (n=117); 12-month DOR rate 69%
- Jideytro is GSK's first lung cancer approval and first asset from the recently completed Nuvalent acquisition
- Additional Nuvalent pipeline assets: neladalkib (NVL-655) for ALK-altered NSCLC under FDA review (PDUFA Nov 27, 2026); NVL-330 for HER2-altered NSCLC
- Positive phase III data for risvutatug rezetecan (Ris-Rez) in relapsed small-cell lung cancer recently reported by licensor Hansoh Pharma
Financial Impact
Near-term revenue contribution likely modest for a $103B company given ROS1+ NSCLC represents ~1-2% of lung cancer cases; strategic value is higher as it validates the Nuvalent acquisition and expands GSK's oncology pipeline into lung cancer.
Risk Factors
- Competition from established ROS1 inhibitors (entrectinib, repotrectinib) with earlier-line approvals
- Pricing and reimbursement headwinds in a concentrated targeted therapy market
- Adverse event profile (edema, peripheral neuropathy, fatigue) may limit adoption vs. better-tolerated alternatives
- Launch execution risk given GSK's limited prior experience in lung cancer commercialisation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006789 |
| Document: 0001654954-26-006789-index-headers.html | 0001654954-26-006789 |
| Document: 0001654954-26-006789-index.html | 0001654954-26-006789 |
| Document: 0001654954-26-006789.txt | 0001654954-26-006789 |
Track record
64 reports on GSK
8 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers